A

ERK MAPK signaling
ABL signaling
Mitosis
Chromatin other
DNA replication
Apoptosis regulation
Chromatin histone acetylation
p53 pathway
JNK and p38 signaling
Protein stability and degradation
Metabolism
Cell cycle
Cytoskeleton
EGFR signaling
Unclassified
WNT signaling
Chromatin histone methylation
PI3K/MTOR signaling
Other, kinases
Other
RTK signaling
Genome integrity
IGF1R signaling
Hormone−related

LCML (n=10)
LUSC (n=15)
LGG (n=17)
LIHC (n=17)
NB (n=29)
ALL (n=24)
MESO (n=21)
ESCA (n=35)
STAD (n=22)
KIRC (n=31)
BLCA (n=19)
PAAD (n=30)
LUAD (n=63)
COAD/READ (n=48)
SKCM (n=52)
BRCA (n=49)
THCA (n=15)
HNSC (n=42)
DLBC (n=32)
SCLC (n=60)
LAML (n=27)
GBM (n=35)
OV (n=32)
CESC (n=13)
MM (n=18)

Pearson r
1
0.5
0
−0.5
−1

B
SPRY4 vs AZ628_29 (ERK MAPK signaling)
BRCA | n = 14 | Pearson r = −0.79 | adj. p = 0.17
SPRY4 expression
Drug response (AUC, lower = more sensitive)

C
SPRY4 vs Ulixertinib_1908 (ERK MAPK signaling)
MM | n = 16 | Pearson r = −0.68 | adj. p = 0.36
SPRY4 expression
Drug response (AUC, lower = more sensitive)